Aptevo Therapeutics Inc. APVO
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -5.70% | 18.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -5.76% | 14.03% | |||
| Operating Income | 5.76% | -14.03% | |||
| Income Before Tax | 5.09% | -15.35% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.09% | -15.35% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.09% | -15.35% | |||
| EBIT | 5.76% | -14.03% | |||
| EBITDA | 5.75% | -15.00% | |||
| EPS Basic | 17.06% | -40.07% | |||
| Normalized Basic EPS | 15.86% | -2.90% | |||
| EPS Diluted | 17.06% | -40.07% | |||
| Normalized Diluted EPS | 15.86% | -2.90% | |||
| Average Basic Shares Outstanding | 12.79% | 12.10% | |||
| Average Diluted Shares Outstanding | 12.79% | 12.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||